Exelixis (EXEL) Cash from Investing Activities (2010 - 2026)
Exelixis (EXEL) posted quarterly Cash from Investing Activities of -$51.1 million for Q2 2026, down 202.62% year-over-year from $49.8 million in Q2 2025, and down 287.47% quarter-over-quarter from $27.2 million in Q1 2026.
Analysis
Exelixis (EXEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$51.1 million for Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 202.62% year-over-year to -$51.1 million; the TTM figure through Apr 2026 stood at $249.6 million (up 239.59% YoY), while the FY2026 annual figure was $350.4 million, up 400.08% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at -$51.1 million, down from $27.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $248.0 million in Q3 2025, with the low at -$245.8 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$49.6 million (2023), against an average of -$21.7 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities slumped 1782.67% in 2022, then soared 325.43% in 2024.
- Exelixis' Cash from Investing Activities stood at -$245.8 million in 2022, then jumped by 125.12% to $61.7 million in 2023, then slumped by 451.73% to -$217.1 million in 2024, then soared by 111.7% to $25.4 million in 2025, then slumped by 301.02% to -$51.1 million in 2026.
- Business Quant data shows EXEL's Cash from Investing Activities at -$51.1 million in Q2 2026, $27.2 million in Q1 2026, and $25.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 91.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 91.43 Mn |
| Apr 3, 2026 | -51.07 Mn |
| Jan 2, 2026 | 27.24 Mn |
| Oct 3, 2025 | 25.41 Mn |
| Jul 4, 2025 | 248.03 Mn |
| Apr 4, 2025 | 49.76 Mn |
| Jan 3, 2025 | -93.20 Mn |
| Sep 27, 2024 | -217.15 Mn |
| Jun 28, 2024 | 81.77 Mn |
| Mar 29, 2024 | 111.79 Mn |
| Dec 29, 2023 | 61.74 Mn |
| Sep 29, 2023 | 34.69 Mn |
| Jun 30, 2023 | -73.79 Mn |
| Mar 31, 2023 | -49.59 Mn |
| Dec 30, 2022 | -245.78 Mn |
| Sep 30, 2022 | -68.95 Mn |
| Jul 1, 2022 | -135.14 Mn |
| Apr 1, 2022 | -74.54 Mn |
| Dec 31, 2021 | -13.06 Mn |
| Oct 1, 2021 | -21.24 Mn |